Published by Alexander Bueso on 26th November 2021
(Sharecast News) - Merck&Co. and development partner Ridgeback Biotherapeutics announced that their experimental oral treatment against Covid-19 reduced the risk of hospitalisation or death by nearly one third.
URL: http://www.digitallook.com/dl/news/story/32292448/...